Health Care • Biotechnology: Pharmaceutical Preparations
$44.89 ▼ -0.45
(-0.99%)
MKT CAP: $7.61B • VOL: 2.16M
52W L $27 52W H $56
ALKS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.48B | $1.56B | $1.66B |
| YoY Revenue Growth % | -5.2% | -6.4% | — |
| Gross Profit | $1.28B | $1.31B | — |
| Gross Margin % | 86.7% | 84.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $254.0M | $420.6M | $414.1M |
| Operating Margin % | 17.2% | 27.0% | 24.9% |
| Net Income (GAAP) | $241.7M | $367.1M | $355.8M |
| EBITDA (Normalized) | $286.3M | $447.4M | $474.0M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $520.8M | $439.1M | $401.4M |
| Capital Expenditures (CapEx) | $40.4M | $33.5M | $74.9M |
| Free Cash Flow (FCF) | $480.3M | $405.6M | $326.5M |
| FCF Margin % | 32.5% | 26.0% | 19.6% |
| Return on Invested Capital (ROIC %) | 14.0% | 23.1% | 12.9% |
| Cash & Short-Term Equivalents | $388.6M | $291.1M | — |
| Total Debt (Short + Long Term) | $0 | $265.8M | $979.6M |
| Total Stockholders' Equity | $1.82B | $1.46B | $2.01B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ALKS.